CLINICAL_TRIALS
research
· 2019-12-05
Clinical Trial Update: Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy [Phase 1, Phase 2]
Summary
Clinical trial update for antisense oligonucleotides in Duchenne Muscular Dystrophy (Phase 1/2) with completed status and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Imperial College London | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-05